CN115666616A - 用于病毒感染的化合物 - Google Patents
用于病毒感染的化合物 Download PDFInfo
- Publication number
- CN115666616A CN115666616A CN202180018734.0A CN202180018734A CN115666616A CN 115666616 A CN115666616 A CN 115666616A CN 202180018734 A CN202180018734 A CN 202180018734A CN 115666616 A CN115666616 A CN 115666616A
- Authority
- CN
- China
- Prior art keywords
- day
- compound
- substituted
- unsubstituted
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382152 | 2020-03-02 | ||
| EP20382152.5 | 2020-03-02 | ||
| EP20382192 | 2020-03-13 | ||
| EP20382192.1 | 2020-03-13 | ||
| EP20382266.3 | 2020-04-02 | ||
| EP20382266 | 2020-04-02 | ||
| EP20382339.8 | 2020-04-27 | ||
| EP20382339 | 2020-04-27 | ||
| EP20382816 | 2020-09-16 | ||
| EP20382815.7 | 2020-09-16 | ||
| EP20382816.5 | 2020-09-16 | ||
| EP20382815 | 2020-09-16 | ||
| EP21382059 | 2021-01-25 | ||
| EP21382059.0 | 2021-01-25 | ||
| PCT/EP2021/055147 WO2021175831A2 (en) | 2020-03-02 | 2021-03-02 | Compounds for use in viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115666616A true CN115666616A (zh) | 2023-01-31 |
Family
ID=74732953
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180018734.0A Pending CN115666616A (zh) | 2020-03-02 | 2021-03-02 | 用于病毒感染的化合物 |
| CN202180018363.6A Pending CN115461067A (zh) | 2020-03-02 | 2021-03-02 | 用于炎症的化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180018363.6A Pending CN115461067A (zh) | 2020-03-02 | 2021-03-02 | 用于炎症的化合物 |
Country Status (17)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4114436A1 (en) * | 2020-03-02 | 2023-01-11 | Pharma Mar S.A. | Compounds for use in the treatment of coronavirus infection |
| CN115666616A (zh) | 2020-03-02 | 2023-01-31 | 法马马有限公司 | 用于病毒感染的化合物 |
| IL296067A (en) * | 2020-03-02 | 2022-11-01 | Pharma Mar Sa | Pld for use in combination in the treatment of coronavirus |
| WO2024165764A1 (en) * | 2023-02-10 | 2024-08-15 | Pharma Mar, S.A. | Plitidepsin for use in the treatment of non-integrated dna viral infections |
| CN117285611B (zh) * | 2023-11-24 | 2024-02-09 | 中国海洋大学 | 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834586A (en) * | 1989-09-29 | 1998-11-10 | Pharma Mar, S.A. | Dehydrodidemnin B |
| CN101389347A (zh) * | 2006-02-28 | 2009-03-18 | 法马马有限公司 | 提高的抗肿瘤治疗 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4493796A (en) | 1980-09-12 | 1985-01-15 | Board Of Trustees, Univ. Of Ill. | Didemnins A, B, C, and derivatives thereof, as antiviral agents |
| US20030148933A1 (en) * | 1990-10-01 | 2003-08-07 | Pharma Mar S.A. | Derivatives of dehydrodidemnin B |
| US6156724A (en) * | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| BR9909668A (pt) * | 1998-04-14 | 2000-12-19 | Jomaa Hassan | Uso de compostos de organofósforo para o tratamento terapêutico e profilático de infecções |
| ES2272462T3 (es) | 2000-04-07 | 2007-05-01 | The Trustees Of The University Of Pennsylvania | Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso. |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| JP4623931B2 (ja) * | 2000-12-07 | 2011-02-02 | エンセラデュス、ファーマシューティカルズ、ベスローテン、フェンノートシャップ | 炎症性疾患の治療用組成物 |
| US20070148192A1 (en) * | 2003-02-21 | 2007-06-28 | Laddha Ritu N | Stable ophthalmic composition |
| AU2004224418A1 (en) | 2003-03-21 | 2004-10-07 | Madeleine M. Joullie | Tamandarin analogs and fragments thereof and methods of making and using |
| WO2011020913A2 (en) | 2009-08-21 | 2011-02-24 | Pharma Mar, S.A. | Cyclodepsipeptide antiviral compounds |
| JP5814933B2 (ja) * | 2009-12-15 | 2015-11-17 | ノバルティス アーゲー | 免疫増強化合物の均質な懸濁物およびその使用 |
| US20120040033A1 (en) * | 2010-08-10 | 2012-02-16 | Ernest Timothy Armstrong | Anti-infective mangrove extract against viruses, bacteria and fungi |
| GB201316524D0 (en) * | 2013-09-17 | 2013-10-30 | Medical Res Council | Biomarkers |
| JP2017526728A (ja) * | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| US11771739B2 (en) * | 2017-06-16 | 2023-10-03 | Vanderbilt University | Methods and compositions for treating microbial inflammation |
| CN115666616A (zh) * | 2020-03-02 | 2023-01-31 | 法马马有限公司 | 用于病毒感染的化合物 |
-
2021
- 2021-03-02 CN CN202180018734.0A patent/CN115666616A/zh active Pending
- 2021-03-02 PE PE2022001880A patent/PE20230412A1/es unknown
- 2021-03-02 IL IL296069A patent/IL296069A/en unknown
- 2021-03-02 EP EP21708019.1A patent/EP4114433A2/en active Pending
- 2021-03-02 US US17/908,533 patent/US12630589B2/en active Active
- 2021-03-02 BR BR112022016604A patent/BR112022016604A2/pt unknown
- 2021-03-02 UY UY0001039110A patent/UY39110A/es not_active Application Discontinuation
- 2021-03-02 TW TW110107292A patent/TW202144381A/zh unknown
- 2021-03-02 CA CA3169540A patent/CA3169540A1/en active Pending
- 2021-03-02 AU AU2021232535A patent/AU2021232535A1/en active Pending
- 2021-03-02 JP JP2022552946A patent/JP2023517536A/ja active Pending
- 2021-03-02 AU AU2021231197A patent/AU2021231197A1/en active Pending
- 2021-03-02 MX MX2022010921A patent/MX2022010921A/es unknown
- 2021-03-02 PY PY202102117301A patent/PY2117301A/es unknown
- 2021-03-02 UY UY0001039109A patent/UY39109A/es not_active Application Discontinuation
- 2021-03-02 CN CN202180018363.6A patent/CN115461067A/zh active Pending
- 2021-03-02 WO PCT/EP2021/055147 patent/WO2021175831A2/en not_active Ceased
- 2021-03-02 EP EP21708237.9A patent/EP4114435A1/en active Pending
- 2021-03-02 BR BR112022016675A patent/BR112022016675A2/pt unknown
- 2021-03-02 WO PCT/EP2021/055187 patent/WO2021175857A1/en not_active Ceased
- 2021-03-02 JP JP2022552937A patent/JP2023517535A/ja active Pending
- 2021-03-02 PY PY202102117308A patent/PY2117308A/es unknown
- 2021-03-02 KR KR1020227034317A patent/KR20220151643A/ko active Pending
- 2021-03-02 US US17/908,526 patent/US20230295236A1/en active Pending
- 2021-03-02 CA CA3169544A patent/CA3169544A1/en active Pending
- 2021-03-02 KR KR1020227034280A patent/KR20220150350A/ko active Pending
- 2021-03-02 TW TW110107293A patent/TWI908772B/zh active
- 2021-03-02 MX MX2022010926A patent/MX2022010926A/es unknown
- 2021-03-02 PE PE2022001795A patent/PE20230606A1/es unknown
- 2021-03-02 IL IL296068A patent/IL296068A/en unknown
-
2022
- 2022-09-02 CL CL2022002396A patent/CL2022002396A1/es unknown
- 2022-09-02 CL CL2022002395A patent/CL2022002395A1/es unknown
- 2022-09-30 CO CONC2022/0014031A patent/CO2022014031A2/es unknown
- 2022-09-30 CO CONC2022/0014093A patent/CO2022014093A2/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834586A (en) * | 1989-09-29 | 1998-11-10 | Pharma Mar, S.A. | Dehydrodidemnin B |
| CN101389347A (zh) * | 2006-02-28 | 2009-03-18 | 法马马有限公司 | 提高的抗肿瘤治疗 |
Non-Patent Citations (5)
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI908772B (zh) | 用於病毒感染之化合物 | |
| EP3349751A1 (en) | Cenicriviroc combination therapy for the treatment of fibrosis | |
| JP7433331B2 (ja) | 特発性肺線維症を治療するための組成物及び方法 | |
| CN115243703A (zh) | 用于组合治疗冠状病毒的pld | |
| CN115666615A (zh) | 用于治疗冠状病毒感染的化合物 | |
| CN103724334A (zh) | 新的抗变态反应的苯并环庚并噻吩类化合物 | |
| JP2023517537A (ja) | 自己免疫状態に使用するための化合物 | |
| EA050127B1 (ru) | Соединения для применения при аутоиммунных состояниях | |
| WO2024165764A1 (en) | Plitidepsin for use in the treatment of non-integrated dna viral infections | |
| KR20250002212A (ko) | 인플루엔자 및 폭스바이러스 바이러스 감염을 치료하는 방법 | |
| EA050436B1 (ru) | Соединения для применения при воспалительных состояниях | |
| KR20220043047A (ko) | 스핑고신-1-인산 수용체 효능제의 용도 | |
| CN119326767A (zh) | 用于治疗脏器纤维化相关疾病的药物组合物和方法 | |
| KR20090127072A (ko) | 신규 디아릴 헵타노이드계 화합물 및 그 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |